GSK:NYSE
GSK plc
$50.72
arrow_downward
-0.70%(-0.36) 1D
$49.88
arrow_downward
-1.66% (-0.84)todayPre-market
Closed: Sep 22, 4:00:03 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$50.69
High
$50.99
Low
$50.22
Mkt. cap
102.81B
Avg. vol.
2.93M
Volume
42.20K
Dividend
3.58%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
16.08
52-wk high
$61.70
52-wk low
$39.29
EPS
$3.15
Beta
0.27
Shares outstanding
2.02B
No. of employees
67K
Open
$50.69
High
$50.99
Low
$50.22
Mkt. cap
102.81B
Avg. vol.
2.93M
Volume
42.20K
Dividend
3.58%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
16.08
52-wk high
$61.70
52-wk low
$39.29
EPS
$3.15
Beta
0.27
Shares outstanding
2.02B
No. of employees
67K
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
TradingView
·
2 hours ago
GSK: Accelerated pipeline investment and specialty focus drive growth amid key launches and margin stability
TipRanks
·
21 hours ago
GSK directors boost holdings with coordinated share purchases
Stock Titan
·
21 hours ago
GSK (NYSE: GSK) board members are buying company stock
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com